Table 1.
Clinical characteristics in targetable gene fusion-positive and -negative patients
|
Variables
|
Total, n
|
Fusion involving targetable genes
|
P
value
|
|
|
Positive, n (%)
|
Negative, n (%)
|
|||
| Sex | 0.293 | |||
| Female | 310 | 3 (0.97) | 307 (99.03) | |
| Male | 644 | 13 (2.02) | 631 (97.98) | |
| Age, yr | 0.463 | |||
| ≤ 60 | 451 | 6 (1.56) | 445 (98.44) | |
| > 60 | 503 | 10 (1.98) | 493 (98.01) | |
| MSI status | 0.551 | |||
| MSI-H | 46 | 1 (2.17) | 45 (97.93) | |
| MSS | 908 | 15 (1.65) | 893 (98.35) | |
| TMB | 0.217 | |||
| Median TMB score | 2.92 | 5.63 | 2.83 | |
Age, sex, microsatellite instability status, and tumor mutational burden between fusion-positive and -negative patients were compared. The one-tailed P value for Fisher’s exact test was calculated. MSI-H: Microsatellite instability-high; MSS: Microsatellite stability; TMB: Tumor mutational burden.